Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Serena Janho dit Hreich"'
Autor:
Serena Janho dit Hreich, Thierry Juhel, Sylvie Leroy, Alina Ghinet, Frederic Brau, Veronique Hofman, Paul Hofman, Valerie Vouret-Craviari
Publikováno v:
eLife, Vol 12 (2024)
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease associated with progressive and irreversible deterioration of respiratory functions that lacks curative therapies. Despite IPF being associated with a dysregulated immune
Externí odkaz:
https://doaj.org/article/7d3df8fa9c874209bfde522c7a364128
Autor:
Serena Janho dit Hreich, Olivier Humbert, Tanguy Pacé-Loscos, Renaud Schiappa, Thierry Juhel, Marius Ilié, Victoria Ferrari, Jonathan Benzaquen, Paul Hofman, Valérie Vouret-Craviari
Publikováno v:
Cancers, Vol 16, Iss 12, p 2226 (2024)
The aim of this study was to assess the potential value of circulating active and inactive IL-18 levels in distinguishing pseudo and true tumor progression among NSCLC patients receiving immune checkpoint inhibitor treatments (ICIs). Methods: This an
Externí odkaz:
https://doaj.org/article/ad901c9549114156bb335edeb6bcf207
Publikováno v:
Biological Procedures Online, Vol 25, Iss 1, Pp 1-10 (2023)
Abstract Background P2RX7 is a purinergic receptor with pleiotropic activities that is activated by high levels of extracellular ATP that are found in inflamed tissues. P2RX7 has immunomodulatory and anti-tumor proprieties and is therefore a therapeu
Externí odkaz:
https://doaj.org/article/eb393dad912e4505bc5ee6e11d940244
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 11, p 9235 (2023)
Cancer is the leading cause of death worldwide despite the variety of treatments that are currently used. This is due to an innate or acquired resistance to therapy that encourages the discovery of novel therapeutic strategies to overcome the resista
Externí odkaz:
https://doaj.org/article/437c6bdef2914f0091d5dffb8209d5fe
Autor:
Laetitia Douguet, Serena Janho dit Hreich, Jonathan Benzaquen, Laetitia Seguin, Thierry Juhel, Xavier Dezitter, Christophe Duranton, Bernhard Ryffel, Jean Kanellopoulos, Cecile Delarasse, Nicolas Renault, Christophe Furman, Germain Homerin, Chloé Féral, Julien Cherfils-Vicini, Régis Millet, Sahil Adriouch, Alina Ghinet, Paul Hofman, Valérie Vouret-Craviari
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
A limited percentage of patients with non-small cell lung cancer respond to immunotherapy. Here the authors show that HEI3090, a chemical positive modulator of the purinergic P2RX7 receptor, promotes IL-18 mediated anti-tumor immune responses and sen
Externí odkaz:
https://doaj.org/article/d9f2cc20554a4d0e92405e7e329a31b4
Publikováno v:
Cancers, Vol 14, Iss 8, p 1926 (2022)
Lung cancer is the most common cancer worldwide. Despite recent therapeutic advances, including targeted therapies and immune checkpoint inhibitors, the disease progresses in almost all advanced lung cancers and in up to 50% of early-stage cancers. T
Externí odkaz:
https://doaj.org/article/252dde54f9ab4bde815220811ed50f9c
Autor:
Mounir El Maï, Serena Janho dit Hreich, Cedric Gaggioli, Armelle Roisin, Nicole Wagner, Jing Ye, Pierre Jalinot, Julien Cherfils-Vicini, Eric Gilson
Publikováno v:
Cancers, Vol 13, Iss 12, p 2998 (2021)
Telomeric repeat-binding factor 2 (TRF2) is a subunit of the shelterin protein complex, which binds to and protects telomeres from unwanted DNA damage response (DDR) activation. TRF2 expression plays a pivotal role in aging and cancer, being downregu
Externí odkaz:
https://doaj.org/article/f4d6a3d57a3040d9a2aff23662f9929b
Autor:
Serena Janho dit Hreich, Thierry Juhel, Sylvie Leroy, Alina Ghinet, Frederic Brau, Véronique Hofman, Paul Hofman, Valérie Vouret-Craviari
Idiopathic pulmonary fibrosis (IPF) is an aggressive interstitial lung disease associated with progressive and irreversible deterioration of respiratory functions that lacks curative therapies. Despite IPF being associated with a dysregulated immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c59c86eae126da1a1821a7524c79b5af
https://doi.org/10.1101/2022.12.15.520590
https://doi.org/10.1101/2022.12.15.520590
Autor:
Simona Saccani, Salomé Lalvée, Charles-Hugo Marquette, Philippe Lenormand, Valérie Vouret-Craviari, Mathilde Butori, Simon Heeke, Véronique Hofman, Jonathan Benzaquen, Thierry Juhel, Jean-Philippe Berthet, Serena Janho Dit Hreich, Serge Bauwens, Paul Hofman, Sylvie Leroy
Publikováno v:
Theranostics
Rationale: The characterization of new theranostic biomarkers is crucial to improving the clinical outcome of patients with advanced lung cancer. Here, we aimed at characterizing the P2RX7 receptor, a positive modulator of the anti-tumor immune respo
Autor:
Jonathan Benzaquen, Jean Kanellopoulos, Nicolas Renault, Christophe Duranton, Cécile Delarasse, Sahil Adriouch, Alina Ghinet, Bernhard Ryffel, Christophe Furman, Régis Millet, Laetitia Seguin, Serena Janho Dit Hreich, Chloé C. Féral, Thierry Juhel, Julien Cherfils-Vicini, Paul Hofman, Germain Homerin, Xavier Dezitter, Valérie Vouret-Craviari, Laetitia Douguet
Publikováno v:
Nature Communications
Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.653. ⟨10.1038/s41467-021-20912-2⟩
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications, 2021, 12 (1), pp.653. ⟨10.1038/s41467-021-20912-2⟩
Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.653. ⟨10.1038/s41467-021-20912-2⟩
Nature Communications, Vol 12, Iss 1, Pp 1-17 (2021)
Nature Communications, 2021, 12 (1), pp.653. ⟨10.1038/s41467-021-20912-2⟩
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive modulator (HEI3090) of the puri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca73021f6590531e19ceaff84cd00c1a
https://hal.sorbonne-universite.fr/hal-03126997/document
https://hal.sorbonne-universite.fr/hal-03126997/document